UF Health recognized as national leader for treatment of rare inherited disorder
UF Health has been recognized as a leader in the treatment of von Hippel-Lindau (VHL) syndrome, a rare inherited disorder associated with tumors, becoming one of only 40 VHL Alliance Clinical Care Centers in the United States.
Joining the VHL Alliance, the preeminent advocacy organization for the disease, strengthens UF Health’s collaborative effort to advance research, share best practices and improve outcomes for patients with VHL worldwide.
“UF Health’s inclusion in the Clinical Care Center network ensures that VHL patients will have access to top-tier care, innovative treatments and comprehensive support services,” said Hans Shuhaiber, M.D., a clinical assistant professor in the department of neurology in the UF College of Medicine and a member of the UF Health Cancer Center. “The partnership not only enhances the quality of care, but also fosters a sense of community and empowerment among those affected by VHL and the clinicians providing VHL patients with groundbreaking treatment options.”
Highlighted Clinical Trials Open for Enrollment
This an open-label, Phase 1 / 2 trial is evaluating the safety and anti-tumor activity of AB-101 monotherapy or AB-101 in combination with Rituximab in patients with RR B-Cell NHL. AB-101 is comprised of ex vivo-expanded allogeneic cord blood-derived natural killer (NK) cells cryopreserved in an infusion-ready suspension. Treatment will involve a lymphodepleting regimen with Cyclophosphamide and Fludarabine, IL2, and AB 101 with or without Rituximab.
Principal Investigator: Erin Dean, M.D. Cell: 813-418-1716
This is a phase II multicenter study of Lutetium Lu 177 Dotate (Lu-177 Dotate) in combination with Triapine vs. Lu-177 Dotate alone in metastatic well-differentiated somatostatin receptor-positive neuroendocrine tumors, after the failure of at least one prior line of systemic treatment. Subjects will be randomized 1:1 to either Lu-177 Dotate w/ oral triapine vs. Lutathera alone. Treatment is given in 8 week cycles, with IV Lu-177 Dotate on Day 1 of each cycle, with Triapine 150 mg QD Days 1-14. Participants can receive up to 4 Cycles of treatment.
Principal Investigator: Kathryn Hitchcock, M.D.
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy for Limited mCRC (ERASur)
This phase III trial compares total ablative therapy (TAT) and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The ablative local therapy will consist of stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for Limited mCRC. This study is based on current common practice, and will pragmatically evaluate the safety, benefits versus risks, and survival impact of the integration of these treatments for Limited mCRC.
Principal Investigator: Kathryn Hitchcock, M.D.
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev)(NUC-3373 Q1 week versus Q2 weeks on a 28-day cycle) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with unresectable metastatic colorectal cancer. The main objectives are to assess and compare the efficacy and safety of the 3 regimens. Pharmacokinetics will be assessed on the 2 NUFIRI arms.
Principal Investigator: Thomas George, M.D., FACP